SGRY Quote, Financials, Valuation and Earnings

Encompass Health has a net margin of -12.55% compared to Surgery Partners's net margin of 10.41%. Surgery Partners's return on equity of -4.8% beat Encompass Health's return on equity of 18.4%.

Surgery Partners has a consensus price target of $31.36, signalling upside risk potential of 46.01%. On the other hand Encompass Health has an analysts' consensus of $123.09 which suggests that it could grow by 8.58%. Given that Surgery Partners has higher upside potential than Encompass Health, analysts believe Surgery Partners is more attractive than Encompass Health.

Surgery Partners has a beta of 2.399, which suggesting that the stock is 139.885% more volatile than S&P 500. In comparison Encompass Health has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.77%.

Surgery Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health offers a yield of 0.58% to investors and pays a quarterly dividend of $0.17 per share. Surgery Partners pays -- of its earnings as a dividend. Encompass Health pays out 13.78% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Surgery Partners quarterly revenues are $864.4M, which are smaller than Encompass Health quarterly revenues of $1.5B. Surgery Partners's net income of -$108.5M is lower than Encompass Health's net income of $151.5M. Notably, Surgery Partners's price-to-earnings ratio is -- while Encompass Health's PE ratio is 23.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners is 0.87x versus 2.10x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

Healthcare Services Group has a net margin of -12.55% compared to Surgery Partners's net margin of 3.85%. Surgery Partners's return on equity of -4.8% beat Healthcare Services Group's return on equity of 8.45%.

Surgery Partners has a consensus price target of $31.36, signalling upside risk potential of 46.01%. On the other hand Healthcare Services Group has an analysts' consensus of $14.50 which suggests that it could grow by 6.07%. Given that Surgery Partners has higher upside potential than Healthcare Services Group, analysts believe Surgery Partners is more attractive than Healthcare Services Group.

Surgery Partners has a beta of 2.399, which suggesting that the stock is 139.885% more volatile than S&P 500. In comparison Healthcare Services Group has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.138%.

Surgery Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healthcare Services Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgery Partners pays -- of its earnings as a dividend. Healthcare Services Group pays out -- of its earnings as a dividend.

Surgery Partners quarterly revenues are $864.4M, which are larger than Healthcare Services Group quarterly revenues of $447.7M. Surgery Partners's net income of -$108.5M is lower than Healthcare Services Group's net income of $17.2M. Notably, Surgery Partners's price-to-earnings ratio is -- while Healthcare Services Group's PE ratio is 24.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners is 0.87x versus 0.58x for Healthcare Services Group. Usually stocks with elevated PS ratios are considered overvalued.

LifeStance Health Group has a net margin of -12.55% compared to Surgery Partners's net margin of -2.19%. Surgery Partners's return on equity of -4.8% beat LifeStance Health Group's return on equity of -4.01%.

Surgery Partners has a consensus price target of $31.36, signalling upside risk potential of 46.01%. On the other hand LifeStance Health Group has an analysts' consensus of $9.14 which suggests that it could grow by 40.01%. Given that Surgery Partners has higher upside potential than LifeStance Health Group, analysts believe Surgery Partners is more attractive than LifeStance Health Group.

Surgery Partners has a beta of 2.399, which suggesting that the stock is 139.885% more volatile than S&P 500. In comparison LifeStance Health Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Surgery Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeStance Health Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgery Partners pays -- of its earnings as a dividend. LifeStance Health Group pays out -- of its earnings as a dividend.

Surgery Partners quarterly revenues are $864.4M, which are larger than LifeStance Health Group quarterly revenues of $325.5M. Surgery Partners's net income of -$108.5M is lower than LifeStance Health Group's net income of -$7.1M. Notably, Surgery Partners's price-to-earnings ratio is -- while LifeStance Health Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners is 0.87x versus 1.98x for LifeStance Health Group. Usually stocks with elevated PS ratios are considered overvalued.

Select Medical Holdings has a net margin of -12.55% compared to Surgery Partners's net margin of 13.09%. Surgery Partners's return on equity of -4.8% beat Select Medical Holdings's return on equity of 11.54%.

Surgery Partners has a consensus price target of $31.36, signalling upside risk potential of 46.01%. On the other hand Select Medical Holdings has an analysts' consensus of $23.17 which suggests that it could grow by 33.53%. Given that Surgery Partners has higher upside potential than Select Medical Holdings, analysts believe Surgery Partners is more attractive than Select Medical Holdings.

Surgery Partners has a beta of 2.399, which suggesting that the stock is 139.885% more volatile than S&P 500. In comparison Select Medical Holdings has a beta of 1.386, suggesting its more volatile than the S&P 500 by 38.57%.

Surgery Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Select Medical Holdings offers a yield of 1.52% to investors and pays a quarterly dividend of $0.06 per share. Surgery Partners pays -- of its earnings as a dividend. Select Medical Holdings pays out 30.19% of its earnings as a dividend. Select Medical Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Surgery Partners quarterly revenues are $864.4M, which are larger than Select Medical Holdings quarterly revenues of -$122.6M. Surgery Partners's net income of -$108.5M is lower than Select Medical Holdings's net income of -$16.1M. Notably, Surgery Partners's price-to-earnings ratio is -- while Select Medical Holdings's PE ratio is 10.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners is 0.87x versus 0.42x for Select Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.